Development of a peptide-based vaccine using a T cell epitope derived from SARS-CoV-2.

Publication date: Jun 20, 2025

Follicular helper T (Tfh) cells are a subset of CD4 T cells that help B cells to produce high-affinity antibodies. Efficient Tfh cell induction by vaccines is critical for protective efficacy against diseases. A Tfh epitope, identified from the SARS-CoV-2 spike protein, has been shown to bind to the corresponding HLA and activates Tfh cells. Here, we assessed the efficacy of a peptide vaccine conjugated with SARS-CoV-2 Tfh epitope against experimental hypertension in a mouse model. The Tfh-angiotensin II (Tfh-Ang II) vaccine activated Tfh and germinal center B cells and induced antibodies against Ang II, thereby suppressing hypertension. However, Ang II-specific autoreactive T cells were not induced. Interestingly, Tfh-Ang II-induced antibody production was enhanced by SARS-CoV-2 spike priming. Moreover, human peripheral blood mononuclear cells from individuals vaccinated with COVID-19 mRNA vaccine were activated by Tfh epitope. Collectively, the SARS-CoV-2 spike-derived universal Tfh epitope may be effective for peptide-based vaccine development.

Open Access PDF

Concepts Keywords
Cd4 Immunology
Efficient Virology
Hypertension
Model
Vaccine

Semantics

Type Source Name
disease IDO cell
disease MESH hypertension
drug DRUGBANK Angiotensin II
disease IDO blood
disease MESH COVID-19

Original Article

(Visited 1 times, 1 visits today)